Neuland Laboratories logo

Neuland Laboratories financials: balance sheet, profit and loss, cash flow

NSE: NEULANDLABBSE: 524558Pharmaceuticals & BiotechnologySmall Cap

Neuland Laboratories Limited · Face value ₹10 · Listed Jul 1994 on BSE, Oct 2008 on NSE
Last close ₹19,315.00up ₹260.00 (1.36%)BSE ₹19,292.05

Share price at the NSE close on 27 Oct 2026. Previous close ₹19,055.00.

27 Oct: open ₹19,055.00, high ₹19,485.00, low ₹19,055.00

52-week range of traded prices to 27 Oct 2026
₹11,500.00Low, 23 Mar 2026₹24,225.00High, 9 Sep 2026
Market cap
₹24,781 Cr356th largest listed
P/E
49.78
P/B
13.22
Dividend yield
0.18%
ROE
29.3%
ROCE
32.1%
Debt to equity
0.10
Volume, NSE
22,94443.0% delivered

Neuland Laboratories' financial statements for the 10 years to Mar 2026, consolidated: the company and its subsidiaries together, with the twelve months to Jun 2026 after them.

10 years at a glance

₹ crore, years to March.Neuland Laboratories annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
57333Mar 1752912Mar 1866716210Mar 1976316246Mar 2093781145Mar 2195164231Mar 221,191164122Mar 231,55930083Mar 241,477260136Mar 252,023364197Mar 26
Peak revenue ₹2,023 Cr, year to Mar 2026; lowest ₹529 Cr, year to Mar 2018

Operating and net margin, per cent

  • Operating margin
  • Net margin
29.7%2.1%15.4%9.5%8.8%13.4%15.7%15.0%22.8%29.7%21.9%28.4%5.7%2.3%2.5%2.1%8.6%6.7%13.7%19.3%17.6%18.0%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 1.8% of operating profit in the first full year.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue2,023
  2. Materials and goods−756
  3. Employee costs−341
  4. Other expenses−352
  5. Operating profit574
  6. Depreciation−92
  7. Other income+30
  8. One-off items0.0
  9. Finance costs−24
  10. Profit before tax489
  11. Tax−125
  12. Net profit364

What the company owns

  • Plant, investments and other assets₹1,524 Cr
  • Receivables₹541 Cr
  • Inventory₹510 Cr
  • Cash and bank₹355 Cr

What pays for it: net worth and liabilities

  • Net worth₹1,874 Cr
  • Other liabilities₹590 Cr
  • Owed to suppliers₹269 Cr
  • Borrowings₹197 Cr

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.Neuland Laboratories quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Jun 2026Twelve monthsFiled 5 Aug
Revenue from operations5735296677639379511,1911,5591,4772,0232,372
4854796086617908089191,0961,1541,4481,609
Materials and goods bought264238366380438422478577588756863
Employee costs––110124150182202257272341374
Other expenses––132157202204239262294352372
Operating profit before depreciation885058102147143272463323574763
Operating margin15.4%9.5%8.8%13.4%15.7%15.0%22.8%29.7%21.9%28.4%32.2%
Materials, % of revenue––54.9%49.8%46.8%44.4%40.1%37.0%39.8%37.3%36.4%
Employee costs, % of revenue––16.6%16.2%16.0%19.2%16.9%16.5%18.4%16.9%15.8%
Other expenses, % of revenue––19.8%20.6%21.6%21.4%20.1%16.8%19.9%17.4%15.7%
Depreciation and amortisation1922263140495360669298
Operating profit after depreciation6928337110794219403258483665
Other income15341621013213031
Finance costs211916221813131482426
Profit before one-off items and tax4914205310582216401270489669
One-off items000000007600
Profit before tax4914205310582216401346489669
17243725185210186125171
Net profit331216168164164300260364498
Other comprehensive income––00−2−6−41011
Total comprehensive income––17167958160301260365499
Net margin5.7%2.3%2.5%2.1%8.6%6.7%13.7%19.3%17.6%18.0%21.0%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the years to Mar 2017 and Mar 2018 they do not, so they are left blank.

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
6997107868419941,2831,5251,874
Share capital1313131313131313
Reserves6866977748289811,2701,5121,862
21024614523112283136197
327358369363439428466710
104163170180147122189345
Total assets1,1301,2311,3251,3831,5801,8332,1802,930
6777167758018199111,0401,447
4535155505837619211,1391,483
Net debt16419111920762−34−230−158
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
18959237261317347
19566281373392450
48−67−6−9158−141
Receivables−30−17−134−955−224
Inventories−28−18−14−71−35−125
Payables37−4054205916
Other working capital69788−31−21191
Tax paid−5−20−44−112−75−104
Interest paid0130000
Capital spending1059666141206390
Free cash flow84−37172120111−43
−84−94−61−150−298−424
−11438−136−692521
Dividends paid346131815
Shares bought back000000
Shares issued000000
Net change in cash−93404244−56
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Consolidated, ₹ per share, years to March.Neuland Laboratories dividend history

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Earnings per share₹36.92–₹13.06₹12.63₹62.85₹49.74₹127.45₹233.89₹202.74₹283.71
Diluted earnings per share₹36.92–₹13.06₹12.63₹62.85₹49.74₹127.45₹233.89₹202.74₹283.71
Dividend per share––₹1.20₹2.00₹5.00₹5.00₹10.00₹14.00₹12.00₹34.00
Book value per share––₹542.08₹550.33₹609.63₹651.53₹770.59₹994.31₹1,181.97₹1,453.02
Dividend payout––9.4%15.9%8.0%10.1%7.9%6.0%6.0%12.1%
Shareholder yield––––0.1%0.3%0.3%0.2%0.1%0.1%
Market cap at the year end (₹ crore)1,3286318683632,6801,3202,3158,11115,48815,431
Earnings per share is left blank for the year to Mar 2018: the earnings per share stated does not match any profit the filing states over the shares in issue, and the share count barely moved during the period.

Ratios

Consolidated, years to March.Neuland Laboratories PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue growth12.3%−7.6%26.0%14.4%22.8%1.5%25.2%30.8%−5.2%37.0%
Operating profit growth9.4%−42.7%15.7%74.6%44.1%−2.9%90.6%70.2%−30.1%77.7%
Net profit growth20.0%−63.2%36.3%−1.4%397.4%−20.8%156.2%83.5%−13.3%39.9%
Earnings per share growth20.0%––−3.3%397.6%−20.9%156.2%83.5%−13.3%39.9%
––2.4%2.3%10.8%7.8%17.8%26.4%18.5%21.4%
–––−0.1 pts8.5 pts−2.9 pts10.0 pts8.5 pts−7.8 pts2.9 pts
From the net margin–––−0.3 pts7.0 pts−2.4 pts8.2 pts7.2 pts−2.2 pts0.4 pts
From asset turnover–––0.2 pts1.3 pts−0.4 pts2.3 pts3.4 pts−4.7 pts1.4 pts
From borrowing–––0.1 pts0.2 pts−0.2 pts−0.5 pts−2.0 pts−0.9 pts1.1 pts
Return on capital employed––3.6%7.4%11.5%8.7%19.6%29.5%15.5%23.3%
Cash conversion––––234.9%91.8%145.1%87.0%122.0%95.2%
Interest cover3.31.52.13.36.06.916.828.831.120.2
Debt to equity––0.300.350.180.270.120.060.090.10
Receivable days––90918590111877898
Inventory days––192211206229213222240247
Payable days––12211112797131121157130
Cash conversion cycle, days––160191164222193188161214
Working capital days––1261308312495978782
Asset turnover––0.590.650.730.700.800.910.740.79
Assets per rupee of net worth––1.621.681.711.661.621.501.431.50
Sales per rupee of plant––2.892.262.332.082.602.982.192.27
Capital spending to depreciation––––2.661.961.242.373.154.25
Plant being built, % of plant in use––45.3%7.0%4.3%4.5%8.9%8.8%6.6%23.5%
No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
14.2%
Cash from operations against operating profit
60.3%
Measure10 years5 years3 years
Revenue growth, yearly rate14.8%16.6%19.3%
Profit growth, yearly rate29.6%35.2%30.6%
Return on equity, average–18.4%22.1%
Return on capital employed, average–19.3%22.8%
Operating margin, average18.0%23.6%26.7%
Net margin, average9.7%15.1%18.3%
Asset turnover, average–0.790.81
Cash conversion cycle, days, average–196188
Interest cover, average12.020.726.7
Debt to equity, average–0.130.09

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations1,221925347
Cash from investing−1,027−872−424
Cash from financing−121−2321
Capital spending900738390
Dividends paid564615
Shares bought back000
Shares issued for cash000
Borrowings raised292209106
Borrowings repaid27113245

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––859856
Altman Z-scorePublished threshold 1.81––2.892.195.003.414.7311.7916.8211.29
Beneish M-scorePublished threshold −1.78––––−2.73−2.52−2.26−2.27−2.81−1.89
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––−1.907.31−0.8211.0512.0117.26
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––––––1.581.061.131.00
Receivables growth less revenue growthOur threshold 0 percentage points–––1.39−8.186.1129.14−27.59−10.2334.49
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––10.15−2.5310.82−8.004.788.293.72
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––−0.020.760.120.111.25−0.600.25
Assets under construction, years of additionsOur threshold 2 years of additions–––0.170.170.200.760.370.210.68
Effective tax ratePublished threshold 17.16 per cent33.6213.4319.1669.3723.4522.3224.2125.2524.9025.56
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––−2.623.99−2.553.324.39
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
25 Aug 2026CRISIL Ratings LimitedBank FacilitiesCrisil A1Review, Re-affirm1
25 Aug 2026CRISIL Ratings LimitedBank FacilitiesCrisil A+Review, OtherPositive400
13 Jul 2026India Ratings and Research Private LimitedBank loan facilitiesIND A+; IND A1New, NewPositive599.99
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.